BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 12377975)

  • 1. Hypersensitivity pneumonitis related to imatinib mesylate.
    Bergeron A; Bergot E; Vilela G; Ades L; Devergie A; Espérou H; Socié G; Calvo F; Gluckman E; Ribaud P; Rousselot P; Tazi A
    J Clin Oncol; 2002 Oct; 20(20):4271-2. PubMed ID: 12377975
    [No Abstract]   [Full Text] [Related]  

  • 2. Reversible drug-induced interstitial pneumonitis following imatinib mesylate therapy.
    Rajda J; Phatak PD
    Am J Hematol; 2005 May; 79(1):80-1. PubMed ID: 15849772
    [No Abstract]   [Full Text] [Related]  

  • 3. Interstitial pneumonitis during imatinib therapy.
    Isshiki I; Yamaguchi K; Okamoto S
    Br J Haematol; 2004 May; 125(4):420. PubMed ID: 15142112
    [No Abstract]   [Full Text] [Related]  

  • 4. Uncommon syndromes and treatment manifestations of malignancy: Case 4. Periorbital edema and imatinib mesylate therapy for chronic myelogenous leukemia.
    Ramar K; Potti A; Mehdi SA
    J Clin Oncol; 2003 Jan; 21(1):172-3. PubMed ID: 12506189
    [No Abstract]   [Full Text] [Related]  

  • 5. Trachyonychia in a patient with chronic myeloid leukaemia after imatinib mesylate.
    Lau YM; Lam YK; Leung KH; Lin SY
    Hong Kong Med J; 2014 Oct; 20(5):464.e2. PubMed ID: 25307080
    [No Abstract]   [Full Text] [Related]  

  • 6. Unusual extramedullary relapses under imatinib mesylate treatment in chronic myeloid leukemia.
    Beyazit Y; Aksu S; Kekilli M; Haznedaroglu IC; Kilickap S; Goker H
    Am J Hematol; 2005 May; 79(1):79-80. PubMed ID: 15849758
    [No Abstract]   [Full Text] [Related]  

  • 7. [A rare complication of imatinib mesylate therapy: drug-induced pneumonitis].
    Stakhina OV; Turkina AG; Kostina IE; Kochkareva IuB
    Ter Arkh; 2010; 82(2):59-61. PubMed ID: 20387680
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Histological features of acute hepatitis after imatinib mesylate treatment.
    James C; Trouette H; Marit G; Cony-Makhoul P; Mahon FX
    Leukemia; 2003 May; 17(5):978-9. PubMed ID: 12750713
    [No Abstract]   [Full Text] [Related]  

  • 9. Multiple skin lesions caused by imatinib mesylate treatment of chronic myeloid leukemia.
    Machaczka M; Gossart M
    Pol Arch Med Wewn; 2013; 123(5):251-2. PubMed ID: 23722191
    [No Abstract]   [Full Text] [Related]  

  • 10. Photosensitization in chronic myelogenous leukaemia patients treated with imatinib mesylate.
    Rousselot P; Larghero J; Raffoux E; Calvo F; Tulliez M; Giraudier S; Rybojad M
    Br J Haematol; 2003 Mar; 120(6):1091-2. PubMed ID: 12648085
    [No Abstract]   [Full Text] [Related]  

  • 11. A patient of chronic myelogenous leukemia developing painful rash on feet.
    Kumar P; Das NK; Sil A; Chakrabarti P
    J Postgrad Med; 2012; 58(4):331-4. PubMed ID: 23298941
    [No Abstract]   [Full Text] [Related]  

  • 12. Imatinib mesylate induced immune thrombocytopenia.
    Rajappa S; Varadpande L; Paul TR; Digumarti R
    Leuk Lymphoma; 2007 Nov; 48(11):2261-3. PubMed ID: 17926182
    [No Abstract]   [Full Text] [Related]  

  • 13. Lack of imatinib-induced thyroid dysfunction in a cohort of non-thyroidectomized patients.
    Dora JM; Leie MA; Netto B; Fogliatto LM; Silla L; Torres F; Maia AL
    Eur J Endocrinol; 2008 May; 158(5):771-2. PubMed ID: 18426838
    [No Abstract]   [Full Text] [Related]  

  • 14. Imatinib mesylate: a new pill for chronic myelogenous leukemia.
    Parmar KK; King RS
    Cancer Pract; 2001; 9(5):263-5. PubMed ID: 11879324
    [No Abstract]   [Full Text] [Related]  

  • 15. Pigmentary changes in chronic myeloid leukemia patients treated with imatinib mesylate.
    Arora B; Kumar L; Sharma A; Wadhwa J; Kochupillai V
    Ann Oncol; 2004 Feb; 15(2):358-9. PubMed ID: 14760137
    [No Abstract]   [Full Text] [Related]  

  • 16. Challenges in oncology. Case 3. Depigmentation in a chronic myeloid leukemia patient treated with STI-571.
    Raanani P; Goldman JM; Ben-Bassat I
    J Clin Oncol; 2002 Feb; 20(3):869-70. PubMed ID: 11821474
    [No Abstract]   [Full Text] [Related]  

  • 17. Successful management of liver injury caused by imatinib mesylate in a patient with previously untreated chronic myelogenous leukemia in the chronic phase.
    Yamazaki R; Okamoto S; Chen CK; Tada S; Saito H; Shibata R; Sakamoto M; Mori T; Ikeda Y
    Leuk Lymphoma; 2006 Jul; 47(7):1427-30. PubMed ID: 16923586
    [No Abstract]   [Full Text] [Related]  

  • 18. Imatinib-induced aplastic anemia in a patient with chronic myeloid leukemia.
    Mabed M; Elhefni AM; Damnhouri G
    Leuk Lymphoma; 2012 Nov; 53(11):2310-1. PubMed ID: 22462614
    [No Abstract]   [Full Text] [Related]  

  • 19. Drug-induced pneumonitis associated with imatinib mesylate in a patient with idiopathic pulmonary fibrosis.
    Yamasawa H; Sugiyama Y; Bando M; Ohno S
    Respiration; 2008; 75(3):350-4. PubMed ID: 16449804
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Precipitation of porphyria cutanea tarda by imatinib mesylate?
    Ho AY; Deacon A; Osborne G; Mufti GJ
    Br J Haematol; 2003 Apr; 121(2):375. PubMed ID: 12694262
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.